Investing.com - Aridis Pharma (OTC: ARDS) reported third quarter EPS of $0.000, $0.10 better than the analyst estimate of $-0.100. Revenue for the quarter came in at $417K versus the...
An analyst from H.C. Wainwright maintained Aridis Pharma (OTC: ARDS) at 'buy' with a price target of $2.000 from a prior price target of %currency%%price%. Prior to this rating, Aridis...
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK,...
Aridis Pharmaceuticals, Inc. (OTC:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections,...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single confirmatory Phase 3 study of...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice (the “Notice”) from the Listing...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) today announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which...
Investing.com - Aridis Pharma reported on Monday third quarter {{erl-1089243||earnings that missed analysts' forecasts and revenue that fell short of expectations. Aridis Pharma announced...
By Sam Boughedda Investing.com — Aridis Pharmaceuticals Inc 's (NASDAQ:ARDS) monoclonal antibody cocktail treatment is potentially first-in-class, H.C. Wainwright analyst Vernon...
By Sam Boughedda Investing.com — Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares have rallied Tuesday morning. The rise is a result of news that the company's antibody cocktail AR-701 is...
Sept 30 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :* ARIDIS PHARMACEUTICALS EXECUTES LICENSE AGREEMENT WITH THE SERUM INSTITUTE OF INDIA, LTD. FOR EXCLUSIVE RIGHTS TO PRODUCTS AND...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Telecoms, Technology and Basic Materials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Oil & Gas, Industrials and Technology sectors propelled shares higher. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
